SCHEMBL6953752

SCHEMBL6953752

Cc1nc(N2CCc3ccccc3CC2)c([N+](=O)[O-])c(=O)n1CCO

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.40
CYP2D6 P10635 1/20 0.40
POLB P06746 3/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 4/20 0.39
GPR55 Q9Y2T6 1/20 0.39
TSHR P16473 2/20 0.38
MAPK1 P28482 2/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
THRB P10828 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C19 P33261 1/20 0.37
HTT P42858 2/20 0.36
PKM P14618 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6949240 0.94 TSHR (0.46) CYP2C9CYP2D6POLBMEN1KMT2A
SCHEMBL6949181 0.93 TSHR (0.43) CYP2C9CYP2D6POLBMEN1KMT2A
SCHEMBL6952584 0.90 CYP2C9 (0.40) CYP2C9CYP2D6POLBMEN1KMT2A
SCHEMBL6952859 0.89 CYP2C9 (0.40) CYP2C9CYP2D6POLBMEN1KMT2A
SCHEMBL6952822 0.88 CYP2C9 (0.39) CYP2C9CYP2D6POLBMEN1KMT2A
SCHEMBL6946348 0.88 MAPT (0.42) CYP2C9CYP2D6POLBMEN1KMT2A
SCHEMBL6950082 0.87 ALDH1A1 (0.39) CYP2C9CYP2D6POLBMEN1KMT2A
SCHEMBL6956884 0.85 GAA (0.52) CYP2C9MEN1KMT2AGAAMAPT
SCHEMBL6949137 0.85 CYP2D6 (0.44) CYP2C9CYP2D6MEN1KMT2AMAPT
SCHEMBL6952446 0.85 CYP2C9 (0.38) CYP2C9CYP2D6POLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1074549-B1 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors HOFFMANN LA ROCHE (CH) 2003-11-19 EP disclosed
US-6218385-B1 FOR THERAPY OR PROPHYLAXIS OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS SUCH AS EPILEPSY, STROKE, CHRONIC AND ACUTE PAIN, PSYCHOSIS, SCHIZOPHRENIA, ALZHEIMER'S DISEASE, COGNITIVE DISORDERS AND MEMORY DEFICITS HOFFMANN-LA ROCHE INC. 2001-04-17 US disclosed
EP-1074549-A2 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors F. HOFFMANN-LA ROCHE AG (CH) 2001-02-07 EP disclosed